Revenue Decline

Showing 1988 articles
Business

Cavco Industries Navigates Weather, Tariffs to Post Solid Q4 Growth; Unveils Major Rebranding Strategy

Cavco Industries reported a 21% year-over-year revenue increase to $508.4 million for fiscal Q4 2025, driven by a 28.5% surge in home shipments. Despite February weather disruptions and ongoing economic uncertainty, the manufactured housing leader saw a strong March rebound, executed a $33 million stock buyback, and launched a company-wide rebranding initiative aimed at simplifying the homebuyer journey.

Business

ASGN Bets Big on AI with Quinnox Acquisition and $1B Buyback: Strategic Pivot or Risky Gamble?

ASGN reaffirms strong Q4 2025 revenue guidance and launches a dual-pronged strategy: a $290 million cash acquisition of AI-focused consultancy Quinnox and a $1 billion share repurchase program. The moves signal a decisive shift towards high-value AI and digital implementation services, even as the company navigates elevated debt and integration challenges under its new Everforth brand.

Business

Gentex Navigates Tariff Headwinds to Deliver Strong Q4, Eyes Growth in Driver Monitoring and Dimmable Tech

Gentex Corporation (GNTX) reported a 19% surge in Q4 2025 revenue to $644.4 million, bolstered by its VOXX acquisition. While core auto-dimming mirror sales held steady, the company achieved a significant five-point outperformance in its primary markets and hit its highest gross margin target since 2021, showcasing resilience against tariff pressures and setting a confident growth trajectory for 2026.

Business

Aon Posts Strong 2025, Eyes Steady Growth Amid Strategic Push

The global professional services firm reported sustained organic revenue growth and margin expansion for 2025, backed by its '3x3' strategic plan and technology investments. Leadership provided an upbeat outlook for 2026, targeting continued mid-single-digit growth and further profitability gains.

Business

Quarterhill's Five-Year Plunge: A 66% Loss Tests Investor Patience

Quarterhill Inc. (TSE:QTRH) shareholders have endured a punishing five-year period, with the stock's value plummeting nearly 70%. Despite modest revenue growth, the market's verdict has been harsh, raising questions about the company's path to profitability and the perils of long-term bets in turbulent sectors.

Business

AbCellera Biologics: A Valuation Crossroads After Volatile Returns

Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.